You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 46 No. 10, October 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Tardive Dyskinesia With Bromocriptine

A Test of the Receptor Modification Strategy

Jeffrey A. Lieberman, MD; Jose Alvir, DPH; Sukdeb Mukherjee, MD; John M. Kane, MD

Arch Gen Psychiatry. 1989;46(10):908-913.


Abstract

• Pathophysiologic theories postulate that tardive dyskinesia arises from the development of chemical denervation supersensitivity of dopamine receptors produced by chronic long-term neuroleptic treatment. To test a dopamine receptor modification strategy, 16 patients with tardive dyskinesia were assigned to treatment with a neuroleptic plus bromocriptine (a dopamine agonist) or placebo for 10 weeks in a rising-dose design. Patients were evaluated weekly during the 10-week treatment period and for 8 weeks after medication withdrawal. No significant treatment effect was found in tardive dyskinesia response in the overall sample. When patients were classified by tardive dyskinesia subtype, patients with choreoathetoid symptoms exhibited only slight improvement with active treatment, which persisted after drug withdrawal; patients with dystonic symptoms showed moderate improvement that was drug and dose dependent. The sustained administration of substantial doses of a dopamine agonist did not produce significant adverse effects, including behavioral toxic effects. These results, although not statistically significant, are of clinical and heuristic interest.



Author Affiliations

From Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, NY (Drs Lieberman, Alvir, and Kane); Special Treatment Unit, Creedmoor Psychiatric Center, Queens Village, NY (Dr Mukherjee); Department of Psychiatry, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY (Drs Lieberman, Alvir, and Kane), and Department of Clinical Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY (Dr Mukherjee).


Footnotes

Accepted for publication August 5, 1988.

Reprint requests to Hillside Hospital, Division of Long Island Jewish Medical Center, PO Box 38, Glen Oaks, NY 11004 (Dr Lieberman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pallidal and thalamic neurostimulation in severe tardive dystonia
Trottenberg et al.
J. Neurol. Neurosurg. Psychiatry 2001;70:557-559.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.